+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Attention Deficit Hyperactivity Disorder Market by Drug Class, Therapeutic Approach, End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast to 2030- Product Image
Attention Deficit Hyperactivity Disorder Market by Drug Class, Therapeutic Approach, End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast to 2030- Product Image
Sale

Attention Deficit Hyperactivity Disorder Market by Drug Class, Therapeutic Approach, End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013867
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives navigating the evolving healthcare sector face a rapidly shifting landscape in Attention Deficit Hyperactivity Disorder (ADHD) management. As the global ADHD market experiences notable transformation in both care delivery and reimbursement models, timely intelligence is crucial for shaping future strategic direction.

Market Snapshot: The Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder market grew from USD 15.61 billion in 2024 to USD 16.29 billion in 2025. It is expected to continue growing at a CAGR of 4.20%, reaching USD 19.99 billion by 2030. These advances reflect a complex interplay of diagnosis rates, innovation in treatments, and global supply chain realignment. The market's dynamic nature is driven by increasing recognition across all age cohorts and the accelerated adoption of digital enablement in patient care models.

Scope & Segmentation

This report delivers comprehensive coverage, systematically analyzing critical segments and regional distinctions influencing ADHD market trends:

  • Drug Class: Non-Stimulants (atomoxetine, clonidine, guanfacine), Stimulants (amphetamines, methylphenidate)
  • Therapeutic Approach: Non-Pharmacological (behavioral therapy, cognitive behavioral therapy, parent training, dietary supplements, neurofeedback), Pharmacological (oral, transdermal)
  • End User: Clinics (inpatient and outpatient), Home Care (home visits, telehealth), Hospitals (secondary and tertiary care)
  • Distribution Channel: Hospital pharmacies, online pharmacies (direct to consumer, marketplace), retail pharmacies
  • Age Group: Adolescents (early and late), Adults (middle-aged, young adults), Children (pre-school, school age)
  • Gender: Female, Male
  • Diagnosis Type: Combined, Predominantly Hyperactive Impulsive, Predominantly Inattentive
  • Geographical Coverage: Americas (including major US states), Europe, Middle East & Africa, and Asia-Pacific (emphasizing diversity in infrastructure and awareness)
  • Leading Companies: Takeda Pharmaceutical Company Limited, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Viatris Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Akili Inc.

Key Takeaways

  • Personalized, patient-centric care models are rapidly gaining traction, driven by the blending of pharmacological and digital therapeutics in ADHD management.
  • Digital health platforms and telehealth services are expanding access, supporting remote diagnosis, behavioral therapy, and ongoing monitoring beyond traditional settings.
  • Value-based reimbursement models are influencing manufacturer strategies, requiring greater investment in real-world data and long-term outcome validation.
  • Regional diversities in regulatory frameworks and provider capacity shape adoption of both stimulant and non-stimulant therapies, as well as broader delivery approaches.
  • Patient advocacy initiatives are increasing policy prioritization and coverage for non-pharmacological interventions, especially in mature healthcare markets.
  • Supply chain resilience, enabled by strategic alliances and expanded manufacturing footprints, is critical to addressing evolving distribution and policy environments.

Tariff Impact: Supply Chain Realignment and Market Consequences

Recent United States tariffs have exposed vulnerabilities in sourcing active pharmaceutical ingredients critical to ADHD treatments. Increased import duties led to pricing pressure and prompted manufacturers to diversify suppliers and invest in local synthesis to minimize future disruptions. These maneuvers have shifted procurement strategies across the landscape, impacting both branded and generic product competitiveness. Strategic patient support programs and forecasting tools are increasingly foundational for mitigating volatility in end-user costs and product availability.

Methodology & Data Sources

This analysis employs robust secondary research through peer-reviewed literature, regulatory filings, and industry reports, enhanced by structured interviews with clinicians and payers. Quantitative findings are validated using triangulation techniques, with rigorous quality controls at each stage to ensure accuracy and actionable relevance for senior stakeholders.

Why This Report Matters

  • Enables strategic decision-making by offering a clear roadmap through a complex and changing ADHD landscape.
  • Highlights actionable levers, such as integrating digital therapeutics or optimizing distribution networks, that align with current patient and payer requirements.
  • Supports risk mitigation and resource allocation to maximize resilience against global supply and policy challenges.

Conclusion

This executive report provides senior leaders with concise, data-driven insight into ADHD market drivers, segmentation, and competitive positioning. With targeted intelligence on evolving technology, region-specific trends, and supply chain resilience, it serves as a strategic foundation for sustained success in a pivotal therapeutic area.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Attention Deficit Hyperactivity Disorder Market, by Drug Class
8.1. Introduction
8.2. Non Stimulants
8.2.1. Atomoxetine
8.2.2. Clonidine
8.2.3. Guanfacine
8.3. Stimulants
8.3.1. Amphetamines
8.3.2. Methylphenidate
9. Attention Deficit Hyperactivity Disorder Market, by Therapeutic Approach
9.1. Introduction
9.2. Non Pharmacological
9.2.1. Behavioral Therapy
9.2.1.1. Cognitive Behavioral Therapy
9.2.1.2. Parent Training
9.2.2. Dietary Supplements
9.2.3. Neurofeedback
9.3. Pharmacological
9.3.1. Oral
9.3.2. Transdermal
10. Attention Deficit Hyperactivity Disorder Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Home Care
10.3.1. Home Visits
10.3.2. Telehealth
10.4. Hospitals
10.4.1. Secondary Care
10.4.2. Tertiary Care
11. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.3.1. Direct To Consumer
11.3.2. Marketplace
11.4. Retail Pharmacies
12. Attention Deficit Hyperactivity Disorder Market, by Age Group
12.1. Introduction
12.2. Adolescents
12.2.1. Early Adolescents
12.2.2. Late Adolescents
12.3. Adults
12.3.1. Middle Aged Adults
12.3.2. Young Adults
12.4. Children
12.4.1. Pre School
12.4.2. School Age
13. Attention Deficit Hyperactivity Disorder Market, by Gender
13.1. Introduction
13.2. Female
13.3. Male
14. Attention Deficit Hyperactivity Disorder Market, by Diagnosis Type
14.1. Introduction
14.2. Combined
14.3. Predominantly Hyperactive Impulsive
14.4. Predominantly Inattentive
15. Americas Attention Deficit Hyperactivity Disorder Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Attention Deficit Hyperactivity Disorder Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Takeda Pharmaceutical Company Limited
18.3.2. Johnson & Johnson
18.3.3. Teva Pharmaceutical Industries Ltd
18.3.4. Novartis International AG
18.3.5. Eli Lilly and Company
18.3.6. Pfizer Inc.
18.3.7. Viatris Inc.
18.3.8. Sandoz International GmbH
18.3.9. Sun Pharmaceutical Industries Ltd
18.3.10. Akili Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET MULTI-CURRENCY
FIGURE 2. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET MULTI-LANGUAGE
FIGURE 3. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATOMOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GUANFACINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PARENT TRAINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NEUROFEEDBACK, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MARKETPLACE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY EARLY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY LATE ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MIDDLE AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PRE SCHOOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COMBINED, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY HYPERACTIVE IMPULSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY INATTENTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 109. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 111. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 112. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 113. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 114. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 116. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 118. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 119. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 122. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 124. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 125. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 126. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 127. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 132. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 133. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 134. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 145. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 146. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 224. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 226. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 227. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 228. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 229. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 230. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 231. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 237. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 239. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 241. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 242. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 243. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 245. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 247. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 248. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 249. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 253. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 258. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 259. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 260. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 261. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Attention Deficit Hyperactivity Disorder market report include:
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Akili Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.99 Billion
Compound Annual Growth Rate4.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2025 - Product Image

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report - Product Image

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2025-2034 - Product Image

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
ADHD Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

ADHD Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 120 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder Global Market Report 2025 - Product Image

Attention Deficit Hyperactivity Disorder Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Market

Attention Deficit Hyperactivity Disorder (ADHD) is a mental disorder that affects a person's ability to focus and control their behavior. Mental Disorders Drugs are used to treat the symptoms of ADHD, such as difficulty concentrating, impulsivity, and hyperactivity. Stimulant medications are the most commonly prescribed drugs for ADHD, and they work by increasing the levels of dopamine and norepinephrine in the brain. Non-stimulant medications, such as atomoxetine, are also used to treat ADHD. The ADHD Drug market is highly competitive, with a number of pharmaceutical companies offering various medications. Companies such as Eli Lilly, Shire, Novartis, and Pfizer are some of the major players in the market. Other companies such as Teva Pharmaceuticals, Sun Pharmaceuticals, and Mylan also offer ADHD medications. These companies are constantly innovating and developing new drugs to meet the needs of patients with ADHD. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.